A new targeted drug that can recognise and attack cancer cells
Successfully tested in animal models, a new-generation drug has achieved complete disease regression in models of neuroblastoma and rhabdomyosarcoma, as well as colon cancer. The key lies in antibody–drug conjugates, which can recognise tumour cells and target them with a chemotherapy molecule designed to act selectively